Cambridge Healthtech Institute’s 8th Annual

Advancing Bispecific Antibodies and Combination Therapy to the Clinic

Creating the Killer Combo

May 6-7, 2020


The development of bispecific antibodies is one of the hottest areas in biologic research at the moment and their advancement to preclinical and clinical development will determine what the future of this area will look like. The 8th Annual Advancing Bispecific Antibodies and Combination Therapy to the Clinic conference brings together leading researchers in this area to strategize on the safety and efficacy of new constructs, review the latest clinical results, and talk about expanding their use beyond oncology.

Preliminary Agenda

INNOVATION IN IMMUNO-ONCOLOGY BISPECIFIC ANTIBODIES

Current Status of Bispecifics Biologics and Combination Biologics Therapies

Rakesh Dixit, PhD, DABT, President & CEO, Bionavigen

Ultraspecific Antibodies for Truly Specific Targeting of Solid Tumors

Jonny Finlay, PhD, CEO, UltraHuman Ltd.

REGN4018 Is a Mucin 16 Bispecific T Cell-Engaging Antibody for the Treatment of Ovarian Cancer

Alison Crawford, PhD, Senior Staff Scientist, Oncology & Angiogenesis, Regeneron Pharmaceuticals

Combinatorial Immune Checkpoint Blockade Using Clinical Stage Bispecific DART® Molecules MGD013 and MGD019

Alexey Berezhnoy, PhD, Scientist III, Cell Biology and Immunology, MacroGenics, Inc.

Development of 4-1BB:HER2

Ingmar Bruns, MD, PhD, Vice President, Clinical Development, Pieris Pharmaceuticals GmbH

Optimization of Preclinical Safety and Efficacy of Anti-HER2/CD3 TDB

Teemu Junttila, PhD, Principal Scientist, Translational Oncology, Genentech, Inc.

Development of CDX-527, a Novel Bispecific Immune Modulating Antibody Targeting PD-L1 and CD27

Joel Goldstein, PhD, Senior Director, R&D, Celldex Therapeutics

Blockade of Glycol-Immune Checkpoints (Siglecs) Using Bifunctional EAGLE for Cancer Immunotherapy

Li Peng, PhD, Senior Vice President, Research and Early Product Development, Palleon Pharmaceuticals

NOVEL MODALITIES AND NOVEL BIOLOGY: MAXIMIZING THE POTENTIAL OF BISPECIFIC TARGETING

KEYNOTE PRESENTATION: Bispecific Antibody Drug Development

Paul W.H.I. Parren, PhD, Executive Vice President, Head, R&D, Lava Therapeutics B.V.

Oncolytic Adenoviruses Armed with BiTes and Bikes

Ramon Alemany, PhD, Scientist, ProCure and Oncobell Programs, Catalan Institute of Oncology - IDIBELL

T Cells Redirected with Modular Biepitopic and Bispecific Antibody Mimic Receptors

Liu Rihe, PhD, Associate Professor, Chemical Biology and Medicinal Chemistry, Eschelman School of Pharmacy, University of North Carolina, Chapel Hill

Selective Blockade of the Immune Checkpoint CD47 Using Bi- and Multi-Specific Antibodies

Nicolas Fischer, PhD, CEO, Light Chain Bioscience, Novimmune SA

A Comprehensive Immunotherapy Strategy for Solid Cancers

Jogender Tushir-Singh, PhD, Assistant Professor, Biochemistry & Molecular Genetics, UVA Cancer Center, University of Virginia School of Medicine



* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean


Update History
2019/11/25
Sponsor updated



View By: